From breakthrough to bottleneck - why cell and gene therapies still struggle at market access скачать в хорошем качестве

From breakthrough to bottleneck - why cell and gene therapies still struggle at market access

Webinar: From breakthrough to bottleneck - why cell and gene therapies still struggle at market access Cell and gene therapies aren’t stalling because the science isn’t working, they’re stalling because access expectations haven’t caught up with reality: high upfront costs, shifting evidence demands, uncertainty around long-term durability, and divergent HTA assessment criteria – dynamics which will continue to be explored at Advanced Therapies Week, February 9 - 12, 2026, San Diego (https://www.phacilitate.com/advanced-.... In this webinar, we examined what’s really blocking market access for CGTs in 2026. Our panel will shared real-world insights on where programs lose momentum and how earlier, smarter collaboration can reduce access risk and avoid late-stage surprises. Tickets still available for Advanced Therapies Week 2026, to book visit https://www.phacilitate.com/advanced-....